
ImmuBYTES Session 3 Video Recording
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.
The ImmuLUNG™ cell model developed by ImmuONE can help predict how lung epithelial and immune cells respond to inhaled substances. Used in-house as part of ImmuONE’s services, ImmuLUNG™ combines human alveolar epithelial cells and alveolar macrophage-like cells in a 3D environment.
Human alveolar-like macrophages
Human alveolar epithelial cells
ImmuLUNG™ combines human alveolar epithelial cells and alveolar macrophage-like cells in a 3D environment. The interactions between these two cell types provide better physiological representation, enabling a more accurate and in-depth understanding of how inhaled products interact with the airways in the deep lung.
The model is composed of alveolar macrophage-like cells assembled in vitro in well plates, that closely represent the form and function of human cells. Substances are added to the well plates, and adverse responses can then be evaluated. ImmuPHAGE™ is fully validated and characterised for cell structure & viability, phagocytic activity and cytokine response. ImmuPHAGE™ is available for purchase as a product and as part of ImmuONE’s service packages.
Watch our video below to see how to use ImmuPHAGE™
ImmuLUNG™ combines human alveolar epithelial cells and alveolar macrophage-like cells in a 3D environment. The resulting cellular crosstalk can better recreate lung tissue functions and immune response modulations.
Available as an in-house service at ImmuONE, these immortalised human alveolar epithelial and macrophage-like cells are preassembled on tissue culture well plates. A range of test materials can be applied to the model in solution, suspension or as an aerosol, and the biological responses of individual cells or the whole system can be monitored.
ImmuLUNG™ is currently available as part of ImmuONE’s service packages – coming soon as a standalone product.
By default, ImmuLUNG™ is available in an air-liquid interface 24-well format for our in-house services. Other formats are available on request.
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.
In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.
Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.
Make Every Breath Safe
Sycamore House
16 Leyden Road
Stevenage, Hertfordshire, UK
SG1 2BP
Copyright 2025 ImmuONE.
All rights reserved.